Serial Cell-free DNA Assessments in Preclinical Models
Related Experiment Video
Updated: Nov 23, 2025
The Lambda Select cII Mutation Detection System
Published on: April 26, 2018
Ariana Rostami1,2, Caberry Yu1, Scott V Bratman1,2,3
1Princess Margaret Cancer Center, University Health Network, 101 College Street, Toronto, ON M5G 1L7, Canada.
Abstract:
Studying circulating cell-free DNA (cfDNA) release within preclinical model systems provides opportunities to investigate the mechanisms and kinetics underlying this process under various conditions. We present a detailed protocol for longitudinal evaluation of cfDNA release through (1) seeding of cancer cell lines and establishment of xenograft tumors, (2) treatment of cancer cells and xenograft tumors, (3) serial collection of cell line media and xenograft blood, and (4) processing and isolation of cfDNA for (5) quantification of cfDNA by quantitative PCR. For complete details on the use and execution of this protocol please refer to Rostami et al. (2020).
